Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci

Blood

Volumn 97, Issue 10, 2001, Pages 3226-3233

  Rush, Laura J ^{a,b,c,d,e,f,g,h}   Dai, Zunyan ^{a,b,c,d,e,f,g,h}   Smiraglia, Dominic J ^{a,b,c,d,e,f,g,h}   Gao, Xin ^{a,b,c,d,e,f,g,h}   Wright, Fred A ^{a,b,c,d,e,f,g,h}   Frühwald, Michael ^{a,b,c,d,e,f,g,h}   Costello, Joseph F ^{a,b,c,d,e,f,g,h}   Held, William A ^{a,b,c,d,e,f,g,h}   Yu, Li ^{a,b,c,d,e,f,g,h}   Krahe, Ralf ^{a,b,c,d,e,f,g,h}   Kolitz, Jonathan E ^{a,b,c,d,e,f,g,h}   Bloomfield, Clara D ^{a,b,c,d,e,f,g,h}   Caligiuri, Michael A ^{a,b,c,d,e,f,g,h}   Plass, Christoph ^{a,b,c,d,e,f,g,h,i}  

^a 2078 Graves Hall   (United States)

^b Department of Veterinary Biosciences ^*  (United States)

^c Division of Hematology and Oncology   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^h Cancer and Leukemia Group B   (United States)

ⁱ THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER REGRESSION; CARCINOGENESIS; CHROMOSOMAL LOCALIZATION; CHROMOSOME 11; CLINICAL ARTICLE; CPG ISLAND; DNA METHYLATION; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

EID: 0035874532     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.10.3226     Document Type: Article

References (62)

1. Bishop JF. The treatment of adult acute myeloid leukemia. Semin Oncol. 1997;24:57-69.
2. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24:17-31.
3. Caligiuri MA, Strout MP, Gilliland DG. Molecular biology of acute myeloid leukemia. Semin Oncol. 1997;24:32-44.
4. Okuda T, Cai Z, Yang S, et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 1998;91:3134-3143.
5. Castilla LH, Wijmenga C, Wang Q, et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell. 1996;87:687-696.
6. Castilla LH, Garrett L, Adya N, et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet. 1999;23:144-146.
7. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-196.
8. Herman JG. Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol. 1999;9:359-367.
9. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci U S A. 1993;90:10914-10921.
10. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16:168-174.
11. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000;184:1-16.
12. Jones PL, Wolffe AP. Relationships between chromatin organization and DNA methylation in determining gene expression. Semin Cancer Biol. 1999;9:339-347.
13. Herman JG, Civin CI, Issa JP, et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837-841.
14. Cameron EE, Baylin SB, Herman JG. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood. 1999;94:2445-2451.
15. Issa JP, Zehnbauer BA, Civin CI, et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res. 1996;56:973-977.
16. Issa JP, Zehnbauer BA, Kaufmann SH, et al. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res. 1997;57:1678-1681.
17. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999;59:3730-3740.
18. Akama TO, Okazaki Y, Ito M, et al. Restriction landmark genomic scanning (RLGS-M)-based genome-wide scanning of mouse liver tumors for alterations in DNA methylation status. Cancer Res. 1997;57:3294-3299.
19. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000;24:132-138.
20. Okazaki Y, Okuizumi H, Sasaki N, et al. An expanded system of restriction landmark genomic scanning (RLGS Ver. 1.8). Electrophoresis. 1995;16:197-202.
21. Plass C, Weichenhan D, Catanese J, et al. An arrayed human Notl-EcoRV boundary library as a tool for RLGS spot analysis. DNA Res. 1997;4:253-255.
22. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol. 1987;196:261-282.
23. Smiraglia DJ, Fruhwald MC, Costello JF, et al. A new tool for the rapid cloning of amplified and hypermethylated human DNA sequences from restriction landmark genome scanning gels. Genomics. 1999;58:254-262.
24. Okazaki Y, Okuizumi H, Sasaki N, et al. Protocols for RLGS gel production. In: Hayashizaki Y, Watanabe S, eds. Restriction Landmark Genomic Scanning (RLGS). New York, NY: Springer; 1997:17-21.
25. Fruhwald MC, O'Dorisio MS, Rush LJ, et al. Gene amplification in PNETs/medulloblastomas: mapping of a novel amplified gene within the MYCN amplicon. J Med Genet. 2000;7:501-509.
26. Freund RJ, Wilson WJ. Statistical Methods. San Diego, CA: Academic Press; 1997.
27. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
28. Asou H, Tashiro S, Hamamoto K, et al. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood. 1991;77:2031-2036.
29. Gallagher R, Collins S, Trujillo J, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 1979;54:713-733.
30. Takeda K, Minowada J, Bloch A. Kinetics of appearance of differentiation-associated characteristics in ML-1, a line of human myeloblastic leukemia cells, after treatment with 12-O-tetradecanoylphorbol-13-acetate, dimethyl sulfoxide or 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1982;42:5152-5158.
31. Taoka T, Tasaka T, Tanaka T, et al. Characterization, growth, and differentiation of a human myeloid leukemia cell line, TI-1 cell. Blood. 1992;80:46-52.
32. Plass C, Yu F, Yu L, et al. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia: involvement of the WIT-1 gene. Oncogene. 1999;18:3159-3165.
33. Stephens JC, Cavanaugh ML, Gradie MI, et al. Mapping the human genome: current status. Science. 1990;250:237-244.
34. Deloukas P, Schuler GD, Gyapay G, et al. A physical map of 30,000 human genes. Science. 1998;282:744-746.
35. Batova A, Diccianni MB, Yu JC, et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 1997;57:832-836.
36. Veigl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A. 1998;95:8698-8702.
37. Chan MF, Liang G, Jones PA. Relationship between transcription and DNA methylation. Curr Top Microbiol Immunol. 2000;249:75-86.
38. Sumiyama K, Washio-Watanabe K, Ono T, et al. Human class III POU genes, POU3F1 and POU3F3, map to chromosomes 1p34.1 and 3p14.2. Mamm Genome. 1998;9:180-181.
39. Papaioannou VE, Silver LM. The T-box gene family. Bioessays. 1998;20:9-19.
40. Yi CH, Terrett JA, Li QY, et al. Identification, mapping, and phylogenomic analysis of four new human members of the T-box gene family: EOMES, TBX6, TBX18, and TBX19. Genomics. 1999;55:10-20.
41. McGrath KE, Palis J. Expression of homeobox genes, including an insulin promoting factor, in the murine yolk sac at the time of hematopoietic initiation. Mol Reprod Dev. 1997;48:145-153.
42. Coles LS, Diamond P, Occhiodoro F, et al. An ordered array of cold shock domain repressor elements across tumor necrosis factor-responsive elements of the granulocyte-macrophage colonystimulating factor promoter. J Biol Chem. 2000;75:14482-14493.
43. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90:489-519.
44. Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999;27:2291-2298.
45. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature. 1999;397:579-583.
46. Walsh CP, Chaillet JR, Bestor TH. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat Genet. 1998;20:116-117.
47. Fruhwald MC, O'Dorisio MS, Dai Z, et al. Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs. Genes Chromosomes Cancer. 2001;30:38-47.
48. Ganderton RH, Briggs RS. CpG island methylation and promoter usage in the parathyroid hormone-related protein gene of cultured lung cells. Biochim Biophys Acta. 1997;1352:303-310.
49. de Bustros A, Nelkin BD, Silverman A, et al. The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia. Proc Natl Acad Sci U S A. 1988;85:5693-5697.
50. Mrozek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Bailliere's Best Pract Res Clinical Haematol. 2001;14:19-47.
51. Fan YS, Rizkalla K, William BF, Engel CJ. Jumping translocations of 11q in acute myeloid leukemia and 1q in follicular lymphoma. Cancer Genet Cytogenet. 2000;118:35-41.
52. Kalantry S, Delva L, Gaboli M, et al. Gene rearrangements in the molecular pathogenesis of acute promyelocytic leukemia. J Cell Physiol. 1997;173:288-296.
53. Schichman SA, Caligiuri MA, Gu Y, et al. ALL-1 partial duplication in acute leukemia. Proc Natl Acad Sci U S A. 1994;91:6236-6239.
54. Caligiuri MA, Strout MP, Schichman SA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res. 1996;56:1418-1425.
55. Pitterle DM, Jolicoeur EM, Bepler G. Hot spots for molecular genetic alterations in lung cancer. In Vivo. 1998;12:643-658.
56. Kim HS, Crow TJ. Human proto-oncogene Int-2/FGF-3: map position 11q13.3-q13.4. Chromosome Res. 1998;6:579.
57. Seshadri R, Lee CS, Hui R, et al. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res. 1996;2:1177-1184.
58. Thakker RV, Bouloux P, Wooding C, et al. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med. 1989;321:218-224.
59. Schaffner C, Idler I, Stilgenbauer S, et al. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci U S A. 2000;97:2773-2778.
60. Lin SF, Lin PM, Liu TC, et al. Clinical implications of aberrant TSG101 transcripts in acute myeloblastic leukemia. Leuk Lymphoma. 2000;36:463-466.
61. Lee MP, DeBaun MR, Mitsuya K, et al. Loss of imprinting of a paternally expressed transcript, with antisense orientation to KVLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin-like growth factor II imprinting. Proc Natl Acad Sci U S A. 1999;96:5203-5208.
62. Smilinich NJ, Day CD, Fitzpatrick GV, et al. A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. Proc Natl Acad Sci U S A. 1999;96:8064-8069.